Compare PLSE & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | VERA |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.0B |
| IPO Year | 2015 | 2021 |
| Metric | PLSE | VERA |
|---|---|---|
| Price | $51.63 | $32.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $22.00 | ★ $81.30 |
| AVG Volume (30 Days) | 612.2K | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $840.00 | N/A |
| Revenue Next Year | $287.54 | $472.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $23.05 |
| 52 Week High | $58.90 | $56.05 |
| Indicator | PLSE | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 45.60 |
| Support Level | $49.01 | $30.05 |
| Resistance Level | $58.90 | $33.09 |
| Average True Range (ATR) | 4.59 | 2.17 |
| MACD | -0.70 | -0.13 |
| Stochastic Oscillator | 35.18 | 25.21 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.